Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.06 (150.00%)

    Silver Spruce Resources

    MCap

    CAD2m

    Last close

    CAD0.02

    ▲ 0.01 (100.00%)

    Actinogen Medical

    MCap

    AUD48m

    Last close

    AUD0.03

    ▲ 0.01 (50.00%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Immunicum – executive interview

Immunicum – executive interview

Associated equity: Mendus

Mendus is a clinical-stage immunoncology (IO) company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell (DC) biology and currently has two lead, cell-based, off-the-shelf therapies for haematological and solid tumours.

View this company

Mendus — 3 videos in collection

Immunicum is a clinical-stage immunoncology company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumours. Its lead clinical asset in development (Phase II, acute myeloid leukaemia) is based on intratumoural priming and cancer relapse vaccination.
In this video, the company’s chief executive officer, Erik Manting, provides an overview of the company’s strategy and differentiated approach.

< Previous
Next >

You may also be interested in these:

Healthcare

Executive interview - Immunicum

Healthcare

Executive interview - Immunicum

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free